Adults as young as 50 may now qualify for an RSV vaccine if they have certain health conditions, according to a quiet update ...

Just in 2024 alone, respiratory syncytial virus (RSV) claimed 2,360 lives of children in hospitals notified in Bengaluru, Kolkata and Mumbai, said Dr Vasant M Khalatkar, National President of the ...

Test positivity for common cold coronaviruses significantly declined following widespread SARS-CoV-2 infection and COVID-19 ...

In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...

As many as 20 people developed a potentially paralysing illness after getting the respiratory syncytial virus (RSV) vaccine.

While there are multiple vaccines approved for preventing RSV in the United States, the only one approved for immunizing infants is Pfizer ’s PFE Abrysvo. Unlike Beyfortus and Enflonsia, which ...

A third monoclonal antibody product to protect babies against respiratory syncytial virus was approved by the Food and Drug Administration on Monday, a development public health experts hope may ...

The U.S. saw limited supply of antibody Beyfortus up to the 2023 RSV season, but the companies have since tripled production capacity and doubled the number of manufacturing sites.

Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which ...

FDA Approves Merck’s Enflonsia for RSV Prevention in Infants: Enflonsia (clesrovimab-cfor) is a long-acting monoclonal antibody approved to prevent respiratory syncytial virus (RSV) lower respiratory ...

RAHWAY, N.J., June 09, 2025--U.S. FDA Approves Merck’s ENFLONSIA for Prevention of RSV Lower Respiratory Tract Disease in Infants Born During or Entering Their First RSV Season ...